Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy

  • Hanqiu Zheng
  • Yangjin Bae
  • Sabine Kasimir-Bauer
  • Rebecca Tang
  • Jin Chen
  • Guangwen Ren
  • Min Yuan
  • Mark Esposito
  • Wenyang Li
  • Yong Wei
  • Minhong Shen
  • Lanjing Zhang
  • Nikolai Tupitsyn
  • Klaus Pantel
  • Chadwick King
  • Jan Sun
  • Jodi Moriguchi
  • Helen Toni Jun
  • Angela Coxon
  • Brendan Lee
  • Yibin Kang

Related Research units

Abstract

Bone metastasis is a major health threat to breast cancer patients. Tumor-derived Jagged1 represents a central node in mediating tumor-stromal interactions that promote osteolytic bone metastasis. Here, we report the development of a highly effective fully human monoclonal antibody against Jagged1 (clone 15D11). In addition to its inhibitory effect on bone metastasis of Jagged1-expressing tumor cells, 15D11 dramatically sensitizes bone metastasis to chemotherapy, which induces Jagged1 expression in osteoblasts to provide a survival niche for cancer cells. We further confirm the bone metastasis-promoting function of osteoblast-derived Jagged1 using osteoblast-specific Jagged1 transgenic mouse model. These findings establish 15D11 as a potential therapeutic agent for the prevention or treatment of bone metastasis.

Bibliographical data

Original languageEnglish
ISSN1535-6108
DOIs
Publication statusPublished - 11.12.2017
PubMed 29232552